Details
Stereochemistry | ACHIRAL |
Molecular Formula | C29H53INO4P |
Molecular Weight | 641.6153 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCOP([O-])(=O)OCCCCCCCCCCCCCCCCCCC1=CC=C([131I])C=C1
InChI
InChIKey=ZOAIEFWMQLYMTF-YRKXUXMHSA-N
InChI=1S/C29H53INO4P/c1-31(2,3)25-27-35-36(32,33)34-26-19-17-15-13-11-9-7-5-4-6-8-10-12-14-16-18-20-28-21-23-29(30)24-22-28/h21-24H,4-20,25-27H2,1-3H3/i30+4
NM404 I-131 (also known as CLR 131) is a phospholipid ether analog labeled with iodine I-131, used as radiotherapeutic and positron emission tomography (PET) radioimaging agent. Upon infusion, the drug accumulates in tumor cells and is retained for a long time because of the decreased activity of a phospholipase D. The drug is being developed by Cellectar Biosciences and is investigated in clinical trials against multiple myeloma and hematologic malignancies. In 2014, the FDA granted orphan drug designation for CLR 131 for the treatment of multiple myeloma.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
455614
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
651018
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
638418
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
646918
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
629018
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
||
|
FDA ORPHAN DRUG |
716119
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
R048696O9L
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
100000178205
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
873438-88-1
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
DB15244
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
16045365
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
11916
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
C84879
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
SUB193827
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY | |||
|
C107500
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
SUPERSEDED | |||
|
HI-246
Created by
admin on Sat Dec 16 00:10:54 GMT 2023 , Edited by admin on Sat Dec 16 00:10:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY